Inflazome, a Dublin, Ireland- and Cambridge, UK-based biotech company developing several small molecule drugs that inhibit harmful inflammation, received an over US$1m grant.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) provided the grant.
The grant will fund the development of a NLRP3-specific Positron Emission Tomography (PET) tracer to allow non-invasive imaging of inflammasome-driven inflammation in the brain.
Led by Prof Matt Cooper, Co-Founder and CEO, Inflazome is developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the NLRP3 inflammasome, which is now understood to drive many chronic and acute inflammatory conditions. The NLRP3 inflammasome was recently shown to be associated with the progression of Parkinson’s Disease in humans and in non-clinical models, in research published on 31 October 2018 in Science Translational Medicine (Link).
The Principal Investigator on this project is Prof. Cooper, who is assisted by Co-Investigator Dr David Miller, Head of Medicinal Chemistry.